Galeano-Valle, Francisco
Demelo-Rodríguez, Pablo
Alonso-Beato, Rubén https://orcid.org/0000-0001-5492-7061
Pedrajas, José María
Fernández-Reyes, José Luis
Chopard, Romain
Sadeghipour, Parham
Hirmerova, Jana
Bikdeli, Behnood
Monreal, Manuel
,
Funding for this research was provided by:
Sanofi
Rovi
Article History
Accepted: 16 July 2024
First Online: 29 July 2024
Declarations
:
: Dr. Galeano-Valle has received speaker's honoraria from the following pharmaceutical companies: ROVI, Techdow, Pfizer, Bristol-Myers, and Daichii-Sankyo. Dr. Demelo-Rodríguez has received speaker's honoraria from the following pharmaceutical companies: ROVI, Bayer, Techdow, Menarini, Leo Pharma, Pfizer, Bristol-Myers, Sanofi, and Daichii-Sankyo. In addition, he has engaged in advisory consultancy work for Techdow, Leo Pharma, and Pfizer. Dr. Bikdeli is supported by a Career Development Award from the American Heart Association and VIVA Physicians (#938814). Dr. Bikdeli was supported by the Scott Schoen and Nancy Adams IGNITE Award and is supported by the Mary Ann Tynan Research Scientist award from the Mary Horrigan Connors Center for Women’s Health and Gender Biology at Brigham and Women’s Hospital, and the Heart and Vascular Center Junior Faculty Award from Brigham and Women’s Hospital. Dr. Bikdeli reports that he is a consulting expert, on behalf of the plaintiff, for litigation related to two specific brand models of IVC filters. Dr. Bikdeli has not been involved in the litigation in 2022 or 2023 nor has he received any compensation in 2022 or 2023. Dr. Bikdeli reports that he is a member of the Medical Advisory Board for the North American Thrombosis Forum, and serves in the Data Safety and Monitory Board of the NAIL-IT trial funded by the National Heart, Lung, and Blood Institute, and Translational Sciences.